SCHEMBL162322

SCHEMBL162322

CCc1ccccc1C(N)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
TSHR P16473 2/20 0.52
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 2/20 0.52
HPGD P15428 1/20 0.52
HSD17B10 Q99714 1/20 0.52
METAP2 P50579 1/20 0.48
PARP1 P09874 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NR1I2 O75469 1/20 0.47
LMNA P02545 1/20 0.47
CHRM2 P08172 1/20 0.47
CYP3A4 P08684 1/20 0.47
ADRA2A P08913 1/20 0.47
OPRK1 P41145 1/20 0.47
HTR2B P41595 1/20 0.47
SLC6A3 Q01959 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
BCAT2 O15382 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6555382 1.00 MAPT (0.52) MAPTTSHRKDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL11603537 0.98 MAPT (0.50) MAPTTSHRKDM4EALDH1A1HPGD
SCHEMBL20581696 0.98 MAPT (0.50) MAPTTSHRKDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL393289 0.98 MAPT (0.50) MAPTTSHRKDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL27504813 0.98 MAPT (0.50) MAPTTSHRKDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL27779824 0.98 MAPT (0.50) MAPTTSHRKDM4EALDH1A1HPGD
Dimethylamine SCHEMBL27639205 0.94 MAPT (0.47) MAPTTSHRKDM4EALDH1A1HPGD
SCHEMBL28203375 0.90 KDM4E (0.44) MAPTTSHRKDM4EALDH1A1HPGD
Diethylamine SCHEMBL7576781 0.89 MAPT (0.42) MAPTTSHRKDM4EALDH1A1HPGD
Fluorobenzene SCHEMBL28219883 0.89 AGTR1 (0.44) MAPTTSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 842 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617798-B2 Imidazopyrazne derivatives HOFFMANN-LA ROCHE INC. (US) 2026-05-05 US claimed
WO-2024261504-A1 BENZOFURAN-3-CARBOXYLIC ACID AMIDES AND BENZOFURAN-3- CARBONYL-BENZAMIDES, METHOD FOR THEIR PRODUCTION WITH HIGH SELECTIVITY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PÉCSI TUDOMÁNYEGYETEM (HU) 2024-12-26 WO claimed
CN-112004813-B Oxadiazole compounds for controlling phytopathogenic fungi PI工业有限公司 2024-03-29 CN claimed
EP-3310822-B1 PROCATALYST FOR POLYMERIZATION OF OLEFINS COMPRISING AN AMINOBENZOATE INTERNAL DONOR AND A 1,3-DIETHER INTERNAL DONOR IN A SPECIFIC RATIO SABIC GLOBAL TECHNOLOGIES BV (NL) 2023-10-11 EP claimed
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2023-07-06 US claimed
WO-2023103261-A1 CRYSTAL FORM B OF ETHYL 2-CYANO-3-AMINO-3-PHENYLACRYLATE, PREPARATION METHOD, AND APPLICATION 江苏省农药研究所股份有限公司 2023-06-15 WO claimed
CN-108658816-B N-aryl amidine substituted trifluoroethyl sulfide derivatives useful as acaricides and insecticides 拜尔农作物科学股份公司 2023-05-02 CN claimed
US-11597723-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) 2023-03-07 US claimed
CN-112294816-B Application of ethyl benzamide compound in preparation of local anesthetic 四川大学华西医院 2021-07-30 CN claimed
CN-112294816-A Application of ethyl benzamide compound in preparation of local anesthetic 四川大学华西医院 2021-02-02 CN claimed
EP-1126833-A4 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES INC (US) 2004-09-08 EP claimed
WO-2004072046-A2 QUINOLINE DERIVATIVES AND THEIR USE FOR MODULATION OF LXR ACTIVITY CAREX S.A. (FR) 2004-08-26 WO claimed
EP-1392655-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2004-03-03 EP claimed
WO-2003087071-A1 SULFONAMIDE DERIVATIVES CELLTECH R & D LIMITED (GB) 2003-10-23 WO claimed
WO-2002062762-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO claimed
US-6380247-B2 A WOOD PRESERVATIVE; POTENTIATION WHEN MIXED WITH AT LEAST ONE OF 3-BROMO-2,3-DIIODO-2-PROPENYL-ETHYLCARBAMATE, 3-IODO-2-PROPYNYLBUTYL-CARBAMATE AND 4-CHLOROPHENYL-3-IODOPROPARGYLFORMAL; MICROBIOCIDES SANKYO COMPANY, LIMITED (JP) 2002-04-30 US claimed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 EP claimed
EP-1126833-A2 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2001-08-29 EP claimed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 WO claimed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCC5, ABCC1 MAPT 4663/4885TSHR 3655/4885KDM4E 4688/4885
US-12617798-B2 Imidazopyrazne derivatives CLIC1, HCFC1, CXCR1 MAPT 4861/4885TSHR 1079/4885KDM4E 3034/4885
US-11597723-B2 Pyrazole derivatives for the treatment of cystic fibrosis CFTR, ABCC5, ABCC3 MAPT 4662/4885TSHR 3688/4885KDM4E 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.